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Abstract 
In the UK, research on hazard group 4 (HG4) pathogens requires specialised Containment 
Level 4 (CL4) facilities. These differ from Biosafety Level 4 (BSL4) conditions in that work is 
conducted in class III microbiological safety cabinets for primary containment instead of 
using positive pressure suits. This presents unique challenges associated with the physical 
restrictions of working in a limited space, and prohibits the use of many techniques and 
specialist equipment. In consequence, detailed studies on the biology of HG4 pathogens and 
in particular their immunological relationships with the host are understudied in the UK; for 
example, the majority of immunological assays with which the immune system is 
interrogated require specialist equipment that is unsuitable for CL4.  
Multiplexing to simultaneously measure multiple analytes is increasingly being used in 
immunological studies. This assay is attractive for CL4 work because it reduces the time 
spent in the laboratory whilst maximising the use of valuable sample volume. The Luminex 
microsphere approach allows for the determination of many cytokines and chemokines, 
however, the detection system uses fixed aligned lasers and integrated computer systems 
which are unsuitable for use at CL4. Therefore, we have developed an approach in which 
the Luminex assay is conducted within the CL4 laboratory and a formalin-fixation stage is 
introduced to allow for analysis to be undertaken outside of containment. Quality control 
preparations allow the assay characteristics to be monitored and analysis of assay 
performance to be evaluated. Our data demonstrate that Luminex is an applicable tool for 
use at CL4 and that assays can be run reliably to generate reproducible standardised data 
across different plates and individual experiments.    
  
1 Introduction 
The measurement of multiple analytes in a single sample has gained increasing popularity recently 
[1, 2]. Multiplexing has several advantages: (i) reduced sample volumes; (ii) reduced workload and 
shortened time spent performing multiple  assays; (iii) assurance that all analytes are measured 
under the same conditions; and (iv) improved control over analytic quality and plausibility [1]. These 
properties make multiplex analysis attractive for use with material generated from clinical studies 
for immunological analysis with hazard group 4 (HG4) pathogen samples, especially as numerous 
cytokines and chemokines are involved in the pathogenesis of viral haemorrhagic fever infections 
[3]. 
One commonly used methodology for multiplex involves bead-based systems in which antibodies 
are bound covalently to fluorescent dyed beads instead of a solid carrier, as in ELISA [4]. The 
Luminex multi-analyte profiling (xMAP) technology uses digital signal processing, capable of 
classifying microsphere beads dyed with distinct ratios of red and near-infrared fluorophores, to 
define ‘spectral addresses’ for each bead population [5]. The replacement of conventional 
polystyrene bead suspension immunoassays (which necessitated several manual washes to prevent 
clogging of the filter plates used) with magnetic bead based immunoassays, enabling separation 
during washing steps, has significantly improved the execution of Luminex assays [2]. 
Work at Containment Level 4 (CL4) needs to follow strict safety and regulatory standards for high-
hazard pathogens. The UK approach of containing the pathogen using a series of class III 
microbiological safety cabinets (MSC) arranged in a cabinet-line as primary containment for hazard 
group 4 (HG4) pathogens, and at the end of work undertaking decontamination with high 
concentrations of disinfectant and formaldehyde fumigation, restricts machine complexity and 
compatibility within this environment. Therefore, the integration of a Luminex analyser into the 
cabinet-line is not practical. 
Opportunities for analysing chemokines and cytokines associated with disease caused by HG4 agents 
have been limited due to physical restrictions and the limited number of assays which can be 
employed in the CL4 environment. Previously, we have demonstrated a proof-of-principle concept 
using Luminex analysis for samples containing, or with the potential to contain, HG4 pathogens [6], 
by inactivating virus with formalin. However, since formalin alters cytokine and chemokine proteins 
such that their detection in immunoassays is impaired [7], we further developed a protocol  that 
used formalin treatment after bead staining and demonstrated its suitability for use with highly 
pathogenic material [6]. One such HG4 agent is Crimean-Congo Haemorrhagic Fever virus (CCHFV), 
the most widespread tick-borne viral infection of humans. It occurs across a vast area from western 
China through southern Asia and the Middle East to south-eastern Europe and most of Africa [8]. 
Since the publication by the World Health Organisation (WHO) of its list of priority pathogens, [9], 
there is increased attention on this pathogen. One area of interest is vaccine development for 
CCHFV [10] including the analysis of immunological profiles associated with pathogenesis, requires 
the measurement of cytokines and chemokines. Whilst some limited work has been undertaken on 
measurement of cytokine levels during CCHFV infection [11-13], the ready availability of relevant 
samples, biocontainment facilities and assay technology has hampered progress. Similar limitations 
exist with other HG4 agents, such as Ebola virus where work on cytokine levels in human infection 
have been restricted to work during outbreaks [14-16]. Unlike Ebola virus which is characterised by 
  
sporadic outbreaks, CCHFV is endemic within regions with more frequent case numbers, thus 
providing increased opportunities for analysis of factors involved with disease progression. 
Our proof-of-concept paper demonstrated that formalin fixation could be utilised for fixing stained 
microbeads and the technique could be used at CL4 [6]. Here we refine the assay by utilising a 
magnetic bead microbead system and performing the assay within the CL4 laboratory alongside HG4 
material. This improvement allowed us to assess the reproducibility of the method enabling precise  
validation of the assay performance [5]. For standardising results the internal control samples 
supplied with the kit were used in order to provide information of intra- and inter-assay variation 
[4]. 
  
  
2. Material and methods 
2.1. Containment Level 4 (CL4) laboratory 
The Luminex assay was conducted within the CL4 laboratory at Public Health England, 
Porton Down. The laboratory design consisting of multiple class III microbiological safety 
cabinets joined together to form a central spine with spurs of working cabinets on both 
sides (Figure 1). At one end of the spine is a dunk tank containing disinfectant which can be 
used to transfer small items into the cabinet line or to remove packaged virus or 
appropriately inactivated material. At the other end is an autoclave for removing waste. To 
remove waste from working cabinets or when changing cabinet use (e.g. between 
pathogens), cabinets are fumigated for at least 8 hours with formaldehyde vapour.  
 
 
Figure 1: The CL4 laboratory at Porton Down showing the central spine with working 
cabinets at right angles.  
 
2.2. Luminex staining 
A 19-plex human cytokine/chemokine panel was used for this study which consisted of 
granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating 
factor (GM-CSF), interferon alpha-2 (IFNa2), interferon-gamma (IFNg), interleukin(IL)-1b, IL-
2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12(p70), IL-15, IL-17A, IFNg-inducible protein 10 (IP-10), 
monocyte chemotactic protein 1 (MCP-1), macrophage inhibitory protein (MIP)-1a, MIP-1b 
and tumor necrosis factor alpha (TNFa) (Millipore, Watford, UK). The assay was performed 
according to the manufacturer’s instructions. As commercial multiplex kits are optimised to 
eliminate or minimise any artefacts from multiplexing, rigorous adherence to the 
  
manufacturers’ protocols is important [5]. Briefly, quality control and standard preparations 
supplied in the kit were reconstituted with deionised water. The two quality control 
preparations, QC1 and QC2, contain an expected amount of analytes in low and high 
concentration, respectively. These details are specific to the reagent lot number and values 
and expected ranges are supplied by the manufacturer. The standard preparation was 
further diluted with assay buffer to produce a range covering concentrations of 10,000, 
2,000, 400, 80, 16 and 3.2 pg/ml. Within the CL4 laboratory, 25 l of standard and quality 
control preparations were added to the relevant wells followed by 25 l of serum matrix 
and 25 l of premixed beads supplied with the kit. Plates were incubated at 4°C overnight 
with continuous rocking before being washed twice with 200 l/well washing buffer using a 
hand held magnet. Washing was performed by allowing the beads to incubate in the 
washing buffer for 30 seconds, before securing the plate onto the magnet for 60 seconds.  
This allowed the beads to settle down onto the bottom of the well. The unbound contents 
were removed by gentle tapping onto absorbent material and more wash buffer was added. 
Following the wash steps, 25 l of detector beads were added to all wells and the plate 
incubator was fixed on a plate shaker for 1 hour at room temperature. Next, 25 l of 
streptavidin-phycoerythrin solution was added to each well and the plate was incubated for 
a further 30 minutes without any washing steps.  
 
2.3 Microbead fixation 
After completion of staining, the microbeads were washed twice with wash buffer. Beads 
were then resuspended with 100 l/well of 10% formalin solution made by dilution of 100% 
formalin (40% w/v formaldehyde solution) (Scientific Laboratory Supplies, Nottingham, 
England) 1:9 v/v with phosphate buffered saline solution (Thermo Fisher, Loughborough, 
England). Plates were fumigated with formaldehyde vapour overnight at room temperature 
for 16 hours with the lids left ajar to allow vapour to reach all surfaces. Following 
fumigation, plates were placed into a sealed bag and removed from the cabinet line for 
manipulation outside of the CL4 laboratory. Results were analysed within 24 hours of 
formalin solution of being added. 
 
2.4 Acquisition and analysis of samples 
Plates were washed twice with wash buffer, and once with sheath fluid in a Containment 
Level 2 laboratory to remove formalin solution before being resuspended in 150 µl of sheath 
fluid. Results were acquired on a Luminex MAGPIX instrument using Exponent software 
(Invitrogen, Paisley, England). At least 50 events per region were collected and median 
fluorescence intensity (MFI) measured. MFI values were converted to concentrations using 
results from a standard cytokine preparation. On each plate, two quality control 
  
preparations containing low and high concentrations of analytes were added, QC1 and QC2, 
respectively. Acceptance criteria of background wells being negative and bead aggregation 
being less than 20% was applied to all plates.  
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3 Results 
3.1 Quantified concentrations of analytes 
For each batch of control preparations, a range of expected values is provided for each of 
the cytokines and chemokines. The actual values obtained in the assays aligned closely to 
the expected ranges for both the low concentration and high concentration control 
preparations, QC1 and QC2, respectively (Figure 2). None of the values were in excess of the 
expected concentrations, whereas some values were marginally below the expected limits. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Concentrations of analytes in control preparations QC1 and QC2. Individual results 
from each Luminex plate are plotted. Grey bars represent the expected ranges provided. 
Red lines indicate the means with error bars denoting standard deviations. Results are 
determined from 16 individual plates.  
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3.2 Intra-assay variation 
Each of the control preparations, QC1 and QC2, were run in duplicate on each plate and the 
coefficient of variation expressed as a percentage (%CV) was obtained (Figure 3). The mean 
%CV across the QC1 samples was 6.36% and that for QC2 was 10.19%; thus the level of 
intra-assay variation was greater when higher analyte concentrations were being measured. 
 
 
 
 
 
 
 
Figure 3: Intra-assay variations in the results between duplicate samples within plates. 
Results show the mean %CV for each of the analytes with error bars denoting standard 
error. Results are determined from 16 individual plates. 
 
3.3 Inter-assay variation 
The control standards were run on 16 independent plates on 6 separate occasions, allowing 
inter-assay variation to be assessed. The results displayed similar variations with both of the 
preparations used, QC1 and QC2 (Figure 4). The mean %CV for QC1 was 15.44 (range 9.24-
23.78) and for QC2 it was 16.19 (range 11.04-20.85).  
 
 
 
 
 
 
Figure 3: Inter-assay variations in the results between assays. Results show the mean %CV 
for each of the analytes. Results are determined from 16 individual plates run on 6 separate 
occasions.  
  
4 Discussion 
The Luminex assay using magnetic beads is well suited to work within the constraints of the 
CL4 laboratory. Unlike the polystyrene bead-system for which a vacuum arrangement is 
required for bead washing [6], our development of a manual washing approach with a hand 
held plate magnet is amenable to work with gauntlets, part of  the necessary constraints at 
CL4. The simplicity of the approach brings additional benefits; for example it avoids the use 
of complex analytical machines in containment which would have inherent difficulties and 
additional risks when working with gauntlets (e.g. pinch points, sharps) including their 
intolerance to formaldehyde fumigation.  
In our Luminex assays at CL4, virus inactivation with formaldehyde solution was employed 
post-bead staining. This avoided the detrimental effects on cytokines if inactivation is 
conducted prior to staining [7] and also enabled the bead-cytokine-antibody binding to be 
fixed so stabilising the reaction before cytokine degradation whilst materials were 
decontaminated via overnight fumigation. The expected ranges for the cytokine standards 
in the kits used in our studies have a range of ±35% of the median value, and the results 
demonstrated the recovery of cytokines from the standards were within these levels. Where 
others have used spike recovery, the frequency has differed by ±25% of expected values 
[17]. Whilst others have observed similarities in relative values but differences in absolute 
values [5, 18], our results fall within the expected ranges using standards that are prepared 
independently of the material used to generate the standard curves used for analysis. 
To evaluate differences between assay performance, the coefficient of variation (CV) value 
was used. This is defined as the standard deviation (SD) divided by the mean; SDs of assays 
generally increase or decrease proportionally to the mean and the division accounts for this 
[19]. The CV is therefore a standardisation of the SD that allows comparison of variability 
estimates regardless of the magnitude of the analyte concentration [19]. CV analysis is thus 
applicable to Luminex analysis where values can vary across a large range. 
To assess repeatability of results, two quality control preparations were run in duplicate on 
plates to determine the intra-assay %CV values. The mean %CV for the two standard 
preparations were 6.36% and 10.19%. Values in the region of 25% have been obtained by 
others [17, 20-23] but higher variances with some cytokine profiles of up to 30.3% [21] and 
37.56% [24] have been reported. Luminex typically suggest values should be ≤10% [25]. The 
calculation of %CV in our set-up relies on duplicates, as this is often the recommended 
practice for commercial assays [2]. 
Due to the number of Luminex assays conducted (n=16) over different days (n=6), the inter-
assay variability could be assessed. Our results showed the largest range in the %CV was 
with the QC1 preparation containing the lower concentrations of cytokines and chemokines 
where values ranged from 9.24% to 23.78%. This is similar to other reported results where 
inter-assay %CV has been ≤20.84% [21].  Our values fall within acceptable limits, where an 
  
interbatch precision of %CV is recommended to be ≤20% [2, 26], or 25% at the lower limit of 
quantification [26]. As concentrations of cytokines and chemokines are often altered in 
order of magnitude, these ranges are in line with similar assays such as ELISA [27].   
It should be noted that the work performed for this manuscript used reagents with the 
same lot numbers. For other Luminex kits, lot-dependent differences have been observed 
[28]. In addition, the bead counts for each of the analytes was at least 50 to reduce 
variablities between wells; lower quantities of beads result in greater CV values [29]. 
Internal calibrator controls along with the matrix-specific conversions are important to allow 
intra- and inter-assay variations to be assessed [22]. Controls to produce standard curves 
and the QC standard preparations used in the assay were diluted with serum matrix, since 
for data integrity, the accuracy of the assay requires the control samples to be measured in 
the same matrix type as the samples investigated [30]. The physical chemical properties (for 
example, pH and total protein content) of the different body fluids such as urine, tears and 
saliva differ, which may have an impact on the outcome of the cytokine assay [4]. 
Our results demonstrate the suitability of Luminex analysis for the measurement of cytokine 
and chemokines in samples infected, or potentially infected, with HG4 pathogens. Any study 
that involves sequential monitoring of patients, or other samples, should be performed 
using only a single technique, one platform, and one commercial supplier for all samples [5]. 
Due to the reliability of the Millipore kits used in this work at CL4 and the inclusion of two 
quality control specimens, this approach will be utilised at PHE in projects to determine the 
contribution of immunological markers in disease pathogenicity of viral haemorrhagic fever. 
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Highlights 
 Luminex analysis can be undertaken safely and effectively with material containing high 
containment biological pathogens. 
 Formalin inactivation after bead staining allows data acquisition outside of the containment 
laboratory. 
 Expected levels of cytokine and chemokines are detected when the assay is used within the 
Containment Level 4 laboratory using magnetic beads with manual washing. 
 Intra- and inter-assay variations are acceptable. 
 
